These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

334 related items for PubMed ID: 28115743

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: biochemical, cellular and behavioral aspects.
    Shiryaev N, Pikman R, Giladi E, Gozes I.
    Curr Pharm Des; 2011; 17(25):2603-12. PubMed ID: 21728979
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Microtubules (tau) as an emerging therapeutic target: NAP (davunetide).
    Gozes I.
    Curr Pharm Des; 2011; 17(31):3413-7. PubMed ID: 21902667
    [Abstract] [Full Text] [Related]

  • 9. D-SAL and NAP: Two Peptides Sharing a SIP Domain.
    Gozes I, Sragovich S, Schirer Y, Idan-Feldman A.
    J Mol Neurosci; 2016 Jun; 59(2):220-31. PubMed ID: 26816081
    [Abstract] [Full Text] [Related]

  • 10. Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model.
    Vulih-Shultzman I, Pinhasov A, Mandel S, Grigoriadis N, Touloumi O, Pittel Z, Gozes I.
    J Pharmacol Exp Ther; 2007 Nov; 323(2):438-49. PubMed ID: 17720885
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The cytoskeleton as a drug target for neuroprotection: the case of the autism- mutated ADNP.
    Gozes I.
    Biol Chem; 2016 Mar; 397(3):177-84. PubMed ID: 25955282
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The femtomolar-acting NAP interacts with microtubules: Novel aspects of astrocyte protection.
    Gozes I, Divinski I.
    J Alzheimers Dis; 2004 Dec; 6(6 Suppl):S37-41. PubMed ID: 15665412
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Introducing ADNP and SIRT1 as new partners regulating microtubules and histone methylation.
    Hadar A, Kapitansky O, Ganaiem M, Sragovich S, Lobyntseva A, Giladi E, Yeheskel A, Avitan A, Vatine GD, Gurwitz D, Ivashko-Pachima Y, Gozes I.
    Mol Psychiatry; 2021 Nov; 26(11):6550-6561. PubMed ID: 33967268
    [Abstract] [Full Text] [Related]

  • 18. Novel tubulin and tau neuroprotective fragments sharing structural similarities with the drug candidate NAP (Davuentide).
    Gozes I, Iram T, Maryanovsky E, Arviv C, Rozenberg L, Schirer Y, Giladi E, Furman-Assaf S.
    J Alzheimers Dis; 2014 Nov; 40 Suppl 1():S23-36. PubMed ID: 24503616
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Tauopathy in the young autistic brain: novel biomarker and therapeutic target.
    Grigg I, Ivashko-Pachima Y, Hait TA, Korenková V, Touloumi O, Lagoudaki R, Van Dijck A, Marusic Z, Anicic M, Vukovic J, Kooy RF, Grigoriadis N, Gozes I.
    Transl Psychiatry; 2020 Jul 13; 10(1):228. PubMed ID: 32661233
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.